Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

October 12, 2017: By Jon Swedien

NicoxNicox and pSivida have agreed to potentially combine Nicox’s nitric oxide (NO)-donating compounds with pSivida’s bioerodible sustained-release drug delivery system to develop an IOP-lowering treatment for glaucoma and ocular hypertension, the companies announced Oct. 10.

Nicox and pSivida will collaborate on the selection of NO-donating product candidates from Nicox’s research portfolio to combine with pSivida’s technology. pSivida will be responsible for initial development activities and receive undisclosed payments from Nicox, the companies said.

pSividaThe firms may elect to conduct more detailed nonclinical studies to generate preclinical data and evaluate additional compounds. Nicox would make additional payments for any incremental development activities for each product candidate selected by Nicox to advance, the companies said.

New intellectual property from the collaboration will be jointly owned, the companies said. Nicox and pSivida will negotiate a separate license agreement for any product candidate they plan to commercialize under the collaboration, they said.

Expected payments from Nicox associated with this agreement are not considered material to Nicox’s financial statements at this time, the company said.

Nicox is an international ophthalmic company based in Paris. pSivida, headquartered in Watertown, Massachusetts, is focused on sustained-release drug products for treating eye diseases.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023